Obese Humans With Nonalcoholic Fatty Liver Disease Display Alterations in Fecal Microbiota and Volatile Organic Compounds

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 7, 2013, Pages 876-878

  Boursier, Jerome ^a   Rawls, John F ^b   Diehl, Anna Mae ^b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; LIPOPOLYSACCHARIDE; RNA 16S; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; VOLATILE ORGANIC COMPOUND;

BACTERIAL OVERGROWTH; EDITORIAL; FECES MICROFLORA; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; INSULIN SENSITIVITY; INTESTINE FLORA; LACHNOSPIRACEAE; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; ROUX Y ANASTOMOSIS;

FATTY LIVER; FECES; FEMALE; HUMANS; MALE; METABOLOME; MICROBIOTA; OBESITY; VOLATILE ORGANIC COMPOUNDS;

EID: 84879204916     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.04.016     Document Type: Editorial

References (39)

1. Drenick E.J., Fisler J., Johnson D. Hepatic steatosis after intestinal bypass-prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982, 82:535-548.
2. Adachi Y., Moore L.E., Bradford B.U., et al. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995, 108:218-224.
3. Cope K., Risby T., Diehl A.M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000, 119:1340-1347.
4. Corrodi P. Jejunoileal bypass: change in the flora of the small intestine and its clinical impact. Rev Infect Dis 1984, 6(Suppl 1):S80-S84.
5. DeMeo M.T., Mutlu E.A., Keshavarzian A., et al. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 2002, 34:385-396.
6. Uesugi T., Froh M., Arteel G.E., et al. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001, 34:101-108.
7. Iimuro Y., Gallucci R.M., Luster M.I., et al. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997, 26:1530-1537.
8. Yin M., Wheeler M.D., Kono H., et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999, 117:942-952.
9. Miura K., Seki E., Ohnishi H., et al. Role of Toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2010, 2010:362847.
10. Csak T., Ganz M., Pespisa J., et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011, 54:133-144.
11. Henao-Mejia J., Elinav E., Jin C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
12. Ridlon J.M., Kang D.J., Hylemon P.B. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006, 47:241-259.
13. Sayin S.I., Wahlström A., Felin J., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013, 17:225-235.
14. Turnbaugh P.J., Ley R.E., Mahowald M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
15. Turnbaugh P.J., Ridaura V.K., Faith J.J., et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009, 1. 6ra14.
16. Upadhyay V., Poroyko V., Kim T.J., et al. Lymphotoxin regulates commensal responses to enable diet-induced obesity. Nat Immunol 2012, 13:947-953.
17. Liou A.P., Paziuk M., Luevano J.M., et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013, 5. 178ra41.
18. Vrieze A., Van Nood E., Holleman F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143:913-916e7.
19. Jumpertz R., Le D.S., Turnbaugh P.J., et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011, 94:58-65.
20. Galambos J.T. Jejunoileal bypass and nutritional liver injury. Arch Pathol Lab Med 1976, 100:229-231.
21. Mezey E., Imbembo A.L., Potter J.J., et al. Endogenous ethanol production and hepatic disease following jejunoileal bypass for morbid obesity. Am J Clin Nutr 1975, 28:1277-1283.
22. Nair S., Cope K., Risby T.H., et al. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:1200-1204.
23. Solga S.F., Alkhuraishe A., Cope K., et al. Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations. Biomarkers 2006, 11:174-183.
24. Volynets V., Küper M.A., Strahl S., et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 2012, 57:1932-1941.
25. Zhu L., Baker S.S., Gill C., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013, 57:601-609.
26. Raman M., Ahmed I., Gillevet P.M., et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013, 11:868-875.
27. Le Roy T., Llopis M., Lepage P., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2012 Nov 29, Epub ahead of print.
28. Benson A.K., Kelly S.A., Legge R., et al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci U S A 2010, 107:18933-18938.
29. Probert C.S., Ahmed I., Khalid T., et al. Volatile organic compounds as diagnostic biomarkers in gastrointestinal and liver diseases. J Gastrointest Liver Dis 2009, 18:337-343.
30. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science 2012, 336:1268-1273.
31. Tremaroli V., Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489:242-249.
32. Duerr C.U., Hornef M.W. The mammalian intestinal epithelium as integral player in the establishment and maintenance of host-microbial homeostasis. Semin Immunol 2012, 24:25-35.
33. Sekirov I., Russell S.L., Antunes L.C., et al. Gut microbiota in health and disease. Physiol Rev 2010, 90:859-904.
34. Cho I., Yamanishi S., Cox L., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012, 488:621-626.
35. Arthur J.C., Perez-Chanona E., Mühlbauer M., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
36. van Nood E., Vrieze A., Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013, 368:407-415.
37. Borody T.J., Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 2012, 9:88-96.
38. Wu G.D., Lewis J.D. Analysis of the human gut microbiome and association with disease. Clin Gastroenterol Hepatol 2013, 11:774-777.
39. McFall-Ngai M., Hadfield M.G., Bosch T.C., et al. Animals in a bacterial world, a new imperative for the life sciences. Proc Natl Acad Sci U S A 2013, 110:3229-3236.